指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

中国重症连续性肾脏替代治疗患者美罗培南延长输注的群体药代动力学:结合肾功能调整给药方案

Population Pharmacokinetics of Prolonged Infusion for Meropenem: Tailoring Dosing Recommendations for Chinese Critically Ill Patients on Continuous Renal Replacement Therapy with Consideration for Renal Function.
指南 / 共识 · Drug Des Devel Ther · 2025-02-17
一句话结论中国重症CRRT患者延长输注美罗培南,0.5 g q6h或1 g q8h可达到100% fT>MIC(MIC≤4 mg/L)且毒性风险极低。

该研究纳入21例中国重症接受CRRT的患者,基于94个美罗培南浓度(1 g q8-12h,输注2-3小时)构建一室群体药代动力学模型,肌酐清除率(CLCR)显著影响美罗培南 endogenous 清除。蒙特卡洛模拟评估延长输注方案(0.5-2 g,3小时输注,q6-12h)达PK/PD目标(100% fT>MIC或100% fT>4×MIC)及肾毒性风险(谷浓度≥45 mg/L)。结果显示CLCR 10-50 mL/min时,0.5 g q6h和1 g q8h对MIC≤4 mg/L可达100% fT>MIC且毒性风险可忽略;2 g q6h或2 g q8h达100% fT>4×MIC但毒性风险>20%。结论提示0.5 g q6h和1 g q8h可能是延长输注的优化方案。

要点

  • 中国重症CRRT患者(CLCR 10-50 mL/min)延长输注美罗培南0.5 g q6h或1 g q8h,对MIC≤4 mg/L可达100% fT>MIC且毒性风险可忽略。
  • 若目标为100% fT>4×MIC,需2 g q6h或2 g q8h,但相关毒性风险很高(>20%)。
  • 群体PK模型显示CLCR显著影响美罗培南 endogenous 清除,一室模型线性消除可充分描述数据。
  • 肾毒性风险定义为谷浓度≥45 mg/L,高剂量方案(2 g q6h/q8h)时该风险>20%。

适用人群与场景

  • 中国重症接受连续性肾脏替代治疗(CRRT)的患者
  • 构建模型数据来自21例患者,接受美罗培南1 g q8-12h,输注2-3小时
  • 模拟评估的CLCR范围为10-50 mL/min

诊断标准与关键阈值

  • PK/PD目标:100% fT>MIC或100% fT>4×MIC
  • 肾毒性风险阈值:谷浓度≥45 mg/L

处置流程与药物剂量

  • 对于CLCR 10-50 mL/min的CRRT患者,延长输注(3小时)美罗培南0.5 g q6h或1 g q8h可达到100% fT>MIC目标(MIC≤4 mg/L),毒性风险可忽略。
  • 若需达到100% fT>4×MIC,需使用2 g q6h或2 g q8h,但相关毒性风险很高(>20%)。

研究设计与关键结果

  • 研究类型:群体药代动力学分析,纳入21例中国重症CRRT患者,共94个美罗培南浓度。
  • 模型:一室模型加线性消除,肌酐清除率(CLCR)显著影响美罗培南 endogenous 清除。
  • 模拟:0.5 g q6h和1 g q8h在CLCR 10-50 mL/min范围内对MIC≤4 mg/L可达100% fT>MIC,毒性风险可忽略。
  • 模拟:2 g q6h和2 g q8h可达100% fT>4×MIC,但毒性风险>20%。

证据类型、等级与局限

  • 证据类型:基于21例患者94个浓度的群体药代动力学建模与蒙特卡洛模拟研究。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对于中国重症CRRT患者(CLCR 10-50 mL/min),作者认为0.5 g q6h和1 g q8h可能是延长输注的优化方案,可达到100% fT>MIC(MIC≤4 mg/L)且毒性风险可忽略; targeting 100% fT>4×MIC需2 g q6h或2 g q8h但毒性风险>20%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Extended meropenem infusion is increasingly employed to enhance clinical outcomes in critically ill patients. Nonetheless, investigations into such dosing regimens in renal-impaired patients undergoing continuous renal replacement therapy (CRRT) are scarce. This study aims to perform a population pharmacokinetic (PK) analysis of prolonged meropenem infusion in critically ill CRRT patients to inform optimal dosing regimens.

METHODS: Ninety-four concentrations from 21 Chinese critically ill CRRT patients receiving 1 g meropenem every 8-12 hours infused over 2-3 hours were utilized to construct the population PK model. Monte Carlo simulations were employed to assess the efficacy based on PK/PD targets (100% fT>MIC or 100% fT>4×MIC) and the risk of nephrotoxicity (trough concentration ≥45 mg/L) for extended meropenem dosing regimens (0.5-2 g with a 3-hour infusion administered every 6-12 hours).

RESULTS: Meropenem concentration data was adequately described by a one-compartment model with linear elimination, and creatinine clearance (CLCR) significantly influenced meropenem's endogenous clearance. 0.5 g q6h and 1 g q8h could achieve desirable attainment of 100% fT>MIC target against an MIC≤4 mg/L, with negligible risk of toxicity for CRRT patients across a CLCR range of 10-50 mL/min. 2 g q6h and 2 g q8h is required for targeting 100% fT>4×MIC for the patients, but the associated risk of toxicity is very high (>20%).

CONCLUSION: A population PK model was developed for prolonged meropenem infusion in Chinese CRRT patients, and 0.5 g q6h and 1 g q8h may be the optimal regimen for prolonged infusion.

来源:Drug Des Devel Ther,查看原文。版权归原作者所有。

参考来源

  1. Peng Y, Liu Y, Cheng Z, et al. Population Pharmacokinetics of Prolonged Infusion for Meropenem: Tailoring Dosing Recommendations for Chinese Critically Ill Patients on Continuous Renal Replacement Therapy with Consideration for Renal Function. Drug Des Devel Ther. 2025. PMID: 39991086. doi:10.2147/DDDT.S489603

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。